Genmab A/S (Genmab A/S) Total Liabilities : $610 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Total Liabilities?

Genmab A/S's Total Liabilities for the quarter that ended in Mar. 2024 was $610 Mil.

Genmab A/S's quarterly Total Liabilities declined from Sep. 2023 ($590.47 Mil) to Dec. 2023 ($538.28 Mil) but then increased from Dec. 2023 ($538.28 Mil) to Mar. 2024 ($609.79 Mil).

Genmab A/S's annual Total Liabilities increased from Dec. 2021 ($369.40 Mil) to Dec. 2022 ($403.96 Mil) and increased from Dec. 2022 ($403.96 Mil) to Dec. 2023 ($538.28 Mil).

Genmab A/S Total Liabilities Historical Data

The historical data trend for Genmab A/S's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Total Liabilities Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

163.03

330.64

369.40

403.96

538.28

Genmab A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															460.86	469.01	590.47	538.28	609.79

Genmab A/S Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genmab A/S's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	363.434	+	(99.491	+	5.121
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	70.229	+	0)
	=	538

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5163.136	-	4624.861
	=	538

Genmab A/S's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	402.198	+	(133.823	+	3.791
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	69.973	+	0)
	=	610

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	5347.095	-	4737.31
	=	610

Genmab A/S Total Liabilities Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.